GENERATION AND OPTIMIZATION OF anti-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY

Vol 3, 2022 - 155208
PD - PostDoctoral
Favorite this paper
How to cite this paper?
Abstract

INTRODUCTION: CAR-T cell immunotherapy has achieved high response rates in treatment-refractory patients with B-cell malignancies. This therapy involves the genetic modification of T cells isolated from patients to express an anti-CD19 CAR (Chimeric Antigen Receptor). Cells are expanded in vitro and then re-infused into the patient. CAR-T cell therapy has shown considerable advance in recent years, being approved by regulatory agencies in US, Europe and recently in Brazil. Most current methods for CAR-T-cell generation use viral vectors for T-cell genetic modification and can take up to 15 days to generate the infusion product. To adapt this protocol to our local reality, we are developing simple and less costly manufacturing protocols to meet the increasing demand for this therapy. OBJECTIVE: To generate anti-CD19 CAR-T cells with a short in vitro expansion protocol based on the non-viral Sleeping Beauty (SB) transposon-based vector system. MATERIAL AND METHODS: The 19BBz CAR sequence was provided by Dr Dario Campana (Memphis, TN) and was cloned in the transposon vector pT4/HB (provided by Wolfgang Uckert (Addgene plasmid#108352). PBMCs were collected from healthy donors after signed board–approved informed consent. Mononuclear cells were isolated by density gradient centrifugation with Ficoll-Hypaque-1077 and electroporated with plasmids enconding 19BBz CAR and the SB100x transposase. The expansion of CAR-T cells was performed using G-REX culture wells for 8 to 12 days. For the xenograft mouse model, eight- to twelve–week-old female NOD-SCID IL2R gamma null (NSG) mice were injected on the tail vein with Nalm-6 Luc-GFP cells and treated 2 days later with 2.5 x105, 5 x105 CAR-T or 3 x106 cells or control cells expanded but not expressing the CARs. For in vivo imaging, mice were injected i.p. with 75 mg/kg d-luciferin and tumor burden was evaluated by bioluminescence using IVIS Lumina XR. For cell analysis, cells or organs were processed and analyzed by flow cytometry. RESULTS AND CONCLUSION: Using the protocol described herein we generate from 9 x107 total PBMCs a mean of 1.34 x107 CAR-T cells after 8 days of expansion. CAR-T cells generated showed cytotoxic effect against CD19+ leukemia cells in vitro. Furthermore, CAR-T cells treatment improved the survival rates (40% at 2,5 x105 dose after 37 days, 77% at 5 x105 dose after 86 days and over 60% at 3 x106 after 85 days) of NSG mice inoculated with 1x 105 Nalm-6 B-cell leukemia. The improved survival was accompanied by a significative reduction in the tumor burden. Finally, infused CAR-T cells persisted for up to 50 days, showing that they are capable of long-term persistence and antitumor response. Our current protocol can generate a cellular product compatible with regulatory requirements and sets the groud to test these CAR-T cells in a phase I clinical assay.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Instituto Nacional do Câncer (INCA)
  • 2 INSTITUTO NACIONAL DE CÂNCER (INCA)
  • 3 INCA Instituto Nacional do Câncer
  • 4 Instituto Nacional de Câncer José Alencar Gomes da Silva
  • 5 Instituto Nacional de Câncer (INCA)
  • 6 INCA
  • 7 INSTITUTO NACIONAL DO CANCER
Track
  • 8. Drugs and/or Natural Products Therapy
Keywords
CAR-T cells
Leukemia
Immunotherapy